AI biotechs launch bioprospecting expeditions with Indigenous groups, agree to share benefits
By Ben Johnson,
Nature
| 02. 14. 2025
A London-based biotech has amassed the world’s largest ethically sourced foundational biodiversity database for training artificial intelligence (AI) by setting up partnerships with 25 countries around the world. The startup, Basecamp Research, announced in January the launch of a new computer cluster that will mine their rich biodiversity database — which contains species collected from extreme locations such as the Arctic tundra and African deserts — to develop new and unique proteins with commercial potential. In agreeing to share revenues from these proteins before conducting its explorations, Basecamp brings an unusual approach to commercial bioprospecting, an activity traditionally associated with injustices towards Indigenous cultures, biopiracy and colonial practices.
The age-old search for medicines derived from nature has entered a new era. Driven by the need to increase the number of proteins to better train machine-learning algorithms, commercial bioprospecting is undergoing a renaissance. Scientists are going into unexplored areas to sample the genomes and proteins of millions of species with the ultimate goal of finding better versions of what is already in nature.
AI-based design has so far been limited to...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...